Smoking Pack‑Year Assessment and Cessation Strategies for High‑Risk Individuals

Calculation of Pack‑Year Index

The American College of Cardiology defines a pack‑year as the product of packs smoked per day and years of smoking (1 pack‑year = 20 cigarettes daily for 1 year)【1】.
Formula: (Packs per day) × (Years smoked) = Pack‑years【1】.
Example: an individual smoking 2 packs/day for 15 years accrues 30 pack‑years【1】.

Lung‑cancer mortality is markedly increased in persons with >20 pack‑years: former smokers have a 3.1‑fold higher risk and current smokers a 5.7‑fold higher risk compared with never‑smokers【2】【3】.
The elevated risk persists: even ≥25 years after quitting, former heavy smokers (>20 pack‑years) retain a 2.2‑fold higher lung‑cancer mortality risk【2】【4】.
Cardiovascular disease (CVD) risk remains raised for 10–14 years after smoking cessation in this high‑exposure group【2】【3】.

Combination pharmacotherapy plus intensive behavioral counseling yields the highest 6‑month abstinence rate (≈36 %) in high‑pack‑year patients【5】【6】.
Varenicline 2 mg/day achieves a 33 % abstinence rate at 6 months (OR 3.1 vs placebo; OR 1.6 vs nicotine patch)【5】【6】.
Long‑term nicotine patch (>14 weeks) with ad‑libitum NRT (gum or spray) produces a 36 % abstinence rate (OR 3.6 vs placebo; OR 1.9 vs standard patch)【5】【6】.
Nicotine patch + bupropion SR results in a 29 % abstinence rate (OR 2.5 vs placebo; OR 1.3 vs standard patch)【5】【6】.
High‑dose nicotine patch (>25 mg) yields a 27 % abstinence rate (OR 2.3 vs placebo)【5】【6】.
Bupropion SR monotherapy provides a 24 % abstinence rate (OR 2.0 vs placebo)【5】【6】.

Intensive group‑based support (≈5 one‑hour sessions over 1 month) that incorporates coping‑skill training and peer support improves cessation outcomes【7】.
The “5 A’s” framework (Ask, Advise, Assess, Assist, Arrange) is endorsed by the European Society of Cardiology for systematic smoking‑cessation counseling【8】.
Sessions should be client‑oriented, emphasizing mutual support rather than didactic teaching; optimal group size is 20–25 participants【7】.
Follow‑up visits are recommended at 2, 3, 6, and 12 months after the program start【7】.

For individuals undergoing lung‑cancer screening with a ≥30 pack‑year history, intensive cessation interventions (counseling + pharmacotherapy) are required; screening alone is insufficient【9】.
Self‑help materials and brief counseling (<5 min) are ineffective in achieving meaningful abstinence【9】.
Adding telephone counseling plus NRT and/or bupropion raises 6‑month cessation rates from ≈7 % to ≈17 % in this high‑risk cohort【9】.

Prolonged pharmacotherapy (>14 weeks) is superior to the standard 8–12‑week course, and some patients may need indefinite treatment to prevent relapse【6】【8】.
Long‑term nicotine‑patch therapy (>14 weeks) maintains a 23.7 % abstinence rate versus 23.4 % with standard duration (minimal difference)【6】.
The health benefits of indefinite NRT outweigh theoretical risks, and NRT is safe in patients with cardiovascular disease【6】【8】.

The Canadian Cardiovascular Society emphasizes that physicians must systematically identify, treat, and arrange follow‑up for smoking cessation in every clinical setting【10】.
A common pitfall is providing insufficiently intensive interventions for heavy smokers, who often require specialist‑level support【7】.